Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Aclarion, Inc. (Nasdaq: ACON) announced that its Nociscan AI solution played a key role in a study to better understand Modic changes (MC) in chronic low back pain (cLBP) patients. The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized Nociscan to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, aimed to clarify the biopsychosocial mechanisms of cLBP. Results suggest that PA levels may be useful in understanding why some MC patients improve or respond to treatment while others do not. Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain could potentially lead to personalized treatment plans for cLBP patients, including the possibility of using antibiotics as a first-line treatment for those with high PA levels.
Aclarion, Inc. (Nasdaq: ACON) ha annunciato che la sua soluzione Nociscan AI ha svolto un ruolo fondamentale in uno studio per comprendere meglio i cambiamenti di Modic (MC) nei pazienti con dolore lombare cronico (cLBP). Lo studio, presentato al 50° Congresso Annuale della International Society for the Study of the Lumbar Spine 2024, ha utilizzato Nociscan per misurare i livelli di acido propionico (PA) intradiscali adiacenti alle piastre terminali vertebrali con MC.
La ricerca, condotta dal REACH Center presso UCSF, mirava a chiarire i meccanismi biopsicosociali del cLBP. I risultati suggeriscono che i livelli di PA potrebbero essere utili per comprendere perché alcuni pazienti con MC migliorano o rispondono al trattamento mentre altri no. La capacità di Nociscan di quantificare in modo non invasivo i biomarcatori chimici associati al dolore discale potrebbe potenzialmente portare a piani di trattamento personalizzati per i pazienti cLBP, inclusa la possibilità di utilizzare antibiotici come trattamento di prima linea per coloro con alti livelli di PA.
Aclarion, Inc. (Nasdaq: ACON) anunció que su solución Nociscan AI desempeñó un papel clave en un estudio para comprender mejor los cambios de Modic (MC) en pacientes con dolor lumbar crónico (cLBP). El estudio, presentado en la 50ª Reunión Anual de la Sociedad Internacional para el Estudio de la Columna Lumbar 2024, utilizó Nociscan para medir los niveles de ácido propiónico (PA) intradiscales adyacentes a las placas terminales vertebrales con MC.
La investigación, llevada a cabo por el REACH Center en UCSF, tenía como objetivo aclarar los mecanismos biopsicosociales del cLBP. Los resultados sugieren que los niveles de PA pueden ser útiles para entender por qué algunos pacientes con MC mejoran o responden al tratamiento mientras que otros no. La capacidad de Nociscan para cuantificar de manera no invasiva los biomarcadores químicos asociados con el dolor discal podría potencialmente conducir a planes de tratamiento personalizados para los pacientes con cLBP, incluida la posibilidad de usar antibióticos como tratamiento de primera línea para aquellos con altos niveles de PA.
Aclarion, Inc. (Nasdaq: ACON)는 Nociscan AI 솔루션이 만성 요통(cLBP) 환자의 Modic 변화(MC)를 더 잘 이해하는 연구에서 중요한 역할을 했다고 발표했습니다. 이 연구는 2024년 제50회 척추 연구 국제 학회 연례 회의에서 발표되었으며, Nociscan을 사용하여 MC가 있는 척추 말단판 인근의 디스크 내 프로피온산(PA) 수준을 측정했습니다.
UCSF의 REACH 센터에서 수행된 연구는 cLBP의 생물심리사회적 메커니즘을 명확히 하는 것을 목표로 했습니다. 연구 결과는 PA 수치가 일부 MC 환자가 개선되거나 치료에 반응하는 이유를 이해하는 데 유용할 수 있음을 시사합니다. Nociscan의 비침습적으로 디스크 통증과 관련된 화학 바이오마커를 정량화할 수 있는 능력은 cLBP 환자에 대한 개인화된 치료 계획으로 이어질 가능성이 있으며, PA 수준이 높은 환자에게 항생제를 1차 치료로 사용할 수 있는 가능성을 포함합니다.
Aclarion, Inc. (Nasdaq: ACON) a annoncé que sa solution Nociscan AI a joué un rôle clé dans une étude visant à mieux comprendre les changements de Modic (MC) chez les patients souffrant de douleurs lombaires chroniques (cLBP). L'étude, présentée lors de la 50e Réunion Annuelle de la Société Internationale pour l'Étude de la Colonne Lombaire 2024, a utilisé Nociscan pour mesurer les niveaux d'acide propionique (PA) intradiscaux adjacents aux plaques terminaux vertébraux avec MC.
La recherche, menée par le REACH Center à UCSF, visait à clarifier les mécanismes biopsychosociaux du cLBP. Les résultats suggèrent que les niveaux de PA pourraient être utiles pour comprendre pourquoi certains patients atteints de MC s'améliorent ou répondent au traitement alors que d'autres ne le font pas. La capacité de Nociscan à quantifier de manière non invasive des biomarqueurs chimiques associés à la douleur discale pourrait potentiellement conduire à des plans de traitement personnalisés pour les patients atteints de cLBP, y compris la possibilité d'utiliser des antibiotiques comme traitement de première ligne pour ceux ayant des niveaux élevés de PA.
Aclarion, Inc. (Nasdaq: ACON) gab bekannt, dass seine Nociscan AI-Lösung eine Schlüsselrolle in einer Studie zur besseren Verständnis von Modic-Veränderungen (MC) bei Patienten mit chronischen Kreuzschmerzen (cLBP) gespielt hat. Die Studie, die auf der 50. Jahrestagung der International Society for the Study of the Lumbar Spine 2024 präsentiert wurde, nutzte Nociscan zur Messung der intradiskalen Propionsäure (PA) Werte in der Nähe der Wirbelendplatten mit MC.
Die Forschung, durchgeführt vom REACH Center an der UCSF, hatte das Ziel, die biopsychosozialen Mechanismen des cLBP zu klären. Die Ergebnisse deuten darauf hin, dass PA-Werte nützlich sein können, um zu verstehen, warum einige MC-Patienten sich verbessern oder auf Behandlungen ansprechen, während andere dies nicht tun. Nociscans Fähigkeit, chemische Biomarker, die mit Bandscheibenschmerzen verbunden sind, nicht invasiv zu quantifizieren, könnte potenziell zu personalisierten Behandlungsplänen für cLBP-Patienten führen, einschließlich der Möglichkeit, Antibiotika als Erstlinientherapie für Patienten mit hohen PA-Werten zu verwenden.
- Nociscan AI solution utilized in a study to better understand Modic changes in chronic low back pain patients
- Research presented at a prestigious international spine conference
- Potential for Nociscan to help stratify patients for personalized treatment plans
- Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain
- None.
Insights
This study utilizing Aclarion's Nociscan AI for understanding Modic changes (MC) in chronic low back pain (cLBP) patients is a significant development in spine research. The ability to non-invasively measure propionic acid (PA) levels in intervertebral discs challenges the long-held belief of disc sterility and opens new avenues for personalized treatment.
Key points:
- 88 cLBP patients were studied using Nociscan's MR spectroscopy
- PA levels were correlated with Modic changes, suggesting potential bacterial involvement
- This could lead to targeted antibiotic treatments for specific cLBP patients
- The study was presented at the prestigious ISSLS Annual Meeting
While promising, it's important to note that this is still research-stage work. The potential for Nociscan to stratify patients and guide treatment decisions could be substantial, but further clinical validation will be necessary. For Aclarion, this study enhances the credibility of their technology and could drive adoption among spine specialists, potentially impacting future revenue streams.
This news has positive implications for Aclarion (NASDAQ: ACON) from a market perspective. Key considerations:
- Market Positioning: Nociscan is positioned as a first-of-its-kind SaaS platform in the spine diagnostics space, giving Aclarion a competitive edge.
- Addressable Market: With 266 million people suffering from spinal degeneration and low back pain globally, the potential market is substantial.
- Clinical Validation: Presentation at ISSLS and collaboration with UCSF lends credibility to Nociscan's technology.
- Future Growth: If Nociscan proves effective in stratifying patients for personalized treatments, it could become a standard tool in spine care, driving adoption and revenue.
However, investors should note that with a market cap of
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP)
MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients
Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024
BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution was utilized to better understand Modic changes (MC) in patients suffering from chronic low back pain (cLBP). The prospective study of 88 patients with low back pain for greater than 3 months was presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024 in Milan, Italy.
“The goal of the REACH Center at UCSF is to clarify the biopsychosocial mechanisms of chronic low back pain — the interconnection between biology, biomechanics, psychology, and socio-environmental factors — which will be foundational for personalized, effective care,” said Aaron Fields, PhD. “Our team is using a variety of validated diagnostic tests to understand the causes of cLBP, including MC. Our prospective study compared intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC. We evaluated disc tissue non-invasively by using MRS and Nociscan. The results challenge the notion that the disc environment is sterile. Furthermore, PA levels may be useful for understanding why some patients with MC improve or respond to treatment while others do not.”
Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain.
Globally, 266 million people suffer from spinal degeneration and low back pain. There are several potential causes and in recent years vertebral endplate irregularities and Modic changes have become an important area of research and development. When Modic changes are present on MRI it is important to understand whether those changes are associated with an infection in the disc. There is currently no noninvasive method to diagnose disc infection. Recognizing that PA is a metabolite of a bacteria commonly found in disc infections, the UCSF team utilized Nociscan to measure PA as a way to stratify patients with Modic changes for potential personalized treatment. Future research may include treating cLBP patients with have high levels of PA with antibiotics as a first line of treatment to evaluate whether this improves clinical outcomes.
“Aclarion’s focus is to provide physicians with new noninvasive information they can use to help make better decisions about patient care,” said Ryan Bond, Chief Strategy Officer. “It is rewarding to see clinicians recognizing the ability of Nociscan technology to identify biomarkers and thinking about how that information can potentially be used to provide personalized treatment plans aimed at improving patient outcomes. We congratulate the UCSF team for their innovative research and important presentation and look forward to additional developments as they become available.”
For more information on ISSLS and the Study: Magnetic resonance spectroscopy biomarker of Modic changes with bacterial etiology
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
What is the significance of Aclarion's Nociscan AI in understanding Modic changes?
Where was the research using Aclarion's Nociscan (ACON) presented?
How does Aclarion's Nociscan (ACON) help in diagnosing chronic low back pain?
What potential treatment approach does the Nociscan (ACON) study suggest for chronic low back pain patients?
